Gestational methylazoxymethanol acetate administration: A developmental disruption model of schizophrenia

Daniel J. Lodge, Anthony A. Grace

Research output: Contribution to journalArticlepeer-review

158 Scopus citations


Animal models are critical for the study of psychiatric disorders since they allow the use of invasive methods that cannot be used for ethical reasons in humans. Currently there are three general models of schizophrenia; (i) those produced with acute pharmacological intervention (i.e. MK-801, ketamine, PCP and amphetamine), (ii) genetic models (i.e. mutant DISC-1, D2-R over expression) and (iii) developmental disruption models (i.e. MAM, neonatal ventral hippocampal lesion, isolation rearing, maternal infection). Here we review evidence for the validity of gestational (day 17) MAM administration as a developmental disruption rodent model of schizophrenia. Offspring from MAM-treated dams are reported to display deficits consistent with those observed in schizophrenia patients, including anatomical changes, behavioral deficits and altered neuronal information processing. Thus gestational MAM administration has been demonstrated to induce a pathodevelopmental process leading to neuroanatomical and behavioral phenotypes consistent with that observed in schizophrenia in humans.

Original languageEnglish (US)
Pages (from-to)306-312
Number of pages7
JournalBehavioural Brain Research
Issue number2
StatePublished - Dec 7 2009
Externally publishedYes


  • Animal model
  • Dopamine
  • Hippocampus
  • MAM
  • Prefrontal cortex
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Behavioral Neuroscience


Dive into the research topics of 'Gestational methylazoxymethanol acetate administration: A developmental disruption model of schizophrenia'. Together they form a unique fingerprint.

Cite this